Publications

Keshari S, Shavkunov AS, Miao Q, Saha A, Minowa T, Molgora M, Williams CD, Chaib M, Highsmith AM, Pineda JE, Alekseev S, Alspach E, Hu KH, Colonna M, Pauken KE, Chen K, Gubin MM. Comparing neoantigen vaccines and immune checkpoint-therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Reports. 2024 Oct 23; PMID: 39446585.

Hagan NB, Inaku C, Kunder N, White T, Iraguha T, Meyer A, Pauken KE, Schenkel JM. In vivo antibody labeling route and fluorophore dictate labeling efficiency, sensitivity, and longevity. bioRxiv. 2024 Aug; PMID 3914319. 

Keshari S, Shavkunov AS, Miao Q, Saha A, Williams CD, Highsmith AM, Pineda JE, Alspach E, Hu KH, Pauken KE, Chen K, Gubin MM. Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy. bioRxiv. 2024 Jan 26; PMID: 38187708.

Shanahan S, Kunder N, Inaku C, Hagan NB, Gibbons G, Mathey-Andrew N, Anandappa G, Soares S, Pauken KE, Jacks T, Schenkel JM. Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer. Journal of Immunology. 2024 July; PMID: 39082930.

Schenkel JM* and Pauken KE*. “Localization, tissue biology and T cell state – implications for cancer immunotherapy.” *co-corresponding, equal contribution. Nature Reviews Immunology. PMID: 37253877. 2023.

Rowe JH, Elia I, Shadid O, Gaudiano EF, Sifnugel NE, Johnson S, Reynolds AG, Fung ME, Joshi S, LaFleur MW, Park JS, Pauken KE, Rabinowitz JD, Freeman GJ, Haigis MC, and Sharpe AH. “Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade.” Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-22-1301. 2023.

Collier JL, Pauken KE, Lee CAA, Patterson DG, Markson SC, Conway TS, Fung ME, France JA, Mucciarone KN, Lian CG, Murphy GF, and Sharpe AH. “Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice.” Journal of Experimental Medicine. https://doi.org/10.1084/jem.20221920. 2023.

Alvarez-Breckenridge CA*, Markson SC*, Stocking JH, Nayyar N, Lastrapes M, Strickland MR, Kim AE, de Sauvage M, Dahal A, Larson JM, Mora JL, Navia AW, Klein, RH, Kuter BM, Gill CM, Bertalan   MS, Shaw B, Kaplan A, Subramanian M, Jain A, Kumar S, Danish H, White M, Shahid O, Pauken KE, Miller BC, Frederick DT, Herbert C, Shaw M, Martinez-Lage M, Frosch MP, Wang N, Gerstner ER, Nahed BV, Curry WT, Carter BS, Cahill DP, Boland GM, Izar B, Davies M, Sharpe AH, Suvà ML, Sullivan RJ, Brastianos PK, Carter SL. *equal contribution. “Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.” Cancer Immunology Research. doi: 10.1158/2326-6066.CIR-21-0870; PMID: 35706413; 2022.

Pauken KE*, Lagattuta KA, Lu BY, Lucca LE, Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH*. “TCR-sequencing in cancer and autoimmunity: barcodes and beyond.” *co-corresponding authors. Trends in Immunology. 43(3):180-194. PMID: 35090787; PMCID: PMC8882139. 2022.

Lagattuta KA, Kang JB, Nathan A, Pauken KE, Jonsson AH, Rao DA, Sharpe AH, Ishigaki K, Raychaudhuri S. “Repertoire analyses reveal TCR sequence features that influence T cell fate.” Nature Immunology. 23(3):446-457. PMID: 35177831; PMCID: PMC8904286; 2022.

Schenkel JM*, Herbst RH*, Canner D, Li A, Hillman M, Shanahan SL, Gibbons G, Smith OC, Kim JY, Westcott PMK, Hwang WL, Freed-Pastor WA, Eng G, Cuoco MS, Rogers P, Park JK, Burger ME, Rozenblatt-Rosen O, Cong L, Pauken KE, Regev A, Jacks T. “Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1⁺ CD8⁺ T cells in tumor-draining lymph nodes.” *equal contribution.  Immunity. 54(10):2338-2353. PMID: 34534439; PMCID: PMC8604155; 2021.

Pauken KE*, Shahid O*, Lagattuta KA*, Mahuron KM*, Luber JM*, Lowe MM, Huang L, Delaney C, Long JM, Fung ME, Newcomer K, Tsai KK, Chow M, Guinn S, Kuchroo JR, Burke KP, Schenkel JM, Rosenblum MD, Daud AI, Sharpe AH, Singer M. “Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment.” *equal contribution. Journal of Experimental Medicine. 218(4):e20200920. PMID: 33651880; PMCID: PMC7933992; 2021.

Collier JL*, Weiss SA*, Pauken KE, Sen DR, Sharpe AH. “Not-so-opposite ends of the spectrum: CD8 T cell    dysfunction across chronic infection, cancer and autoimmunity.” *equal contribution. Review, Nature Immunology. doi: 10.1038/s41590-021-00949-7. PMID: 34140679; PMCID: PMC9197228; 2021.

Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ. “Emerging concepts in PD-1 checkpoint biology.” Review, Seminars in Immunology. doi: 10.1016/j.smim.2021.101480. PMID: 34006473; PMCID: PMC8545711; 2021.

Lo JA, Kawakubo M*, Juneja VR*, Su MY*, Erlich TH*, LaFleur MW, Kemeny LV, Rashid M,  Malehmir M, Rabi SA, Raghavan R, Allouche J,  Kasumova G, Frederick DT, Pauken KE, Weng QY, da Silva MP, Xu Y, van der Sande AAJ, Silkworth W, Roider E, Browne EP, Lieb DJ, Wang B, Garraway LA, Wu CJ, Flaherty KT, Brinckerhoff CE, Mullins DW, Adams DJ, Hacohen N, Hoang MP, Boland GM, Freeman GJ, Sharpe AH, Manstein D, Fisher DE. “Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses.” *equal contribution. Science Translational Medicine. 13(581):eabd8636. PMID: 33597266; PMCID: PMC8130008; 2021.

Johnnidis JB*, Muroyama Y*, Ngiow SF, Chen Z, Manne S, Cai Z, Song S, Platt JM, Schenkel JM, Abdel-Hakeem M, Beltra JC, Greenplate AR, Ali MA, Nzingha K, Giles JR, Harly C, Attanasio J, Pauken KE, Bengsch B, Paley MA, Tomov VT, Kurachi M, Vignali DAA, Sharpe AH, Reiner SL, Bhandoola A, Johnson FB, Wherry EJ. “Inhibitory signaling sustains a distinct early memory CD8⁺ T cell precursor that is resistant to DNA damage.” *equal contribution. Science Immunology. 6(55):eabe3702. PMID: 33452106; PMCID: PMC8258400; 2021.

Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, Pinter M, Sen DR, Singer M, Sharpe AH, Jain RK. “A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.” Proceedings of the National Academy of Sciences. 117(38):23684-23694. PMID: 32907939; PMCID: PMC7519254; 2020.

Pauken KE*, Godec J*, Odorizzi PM*, Brown KE, Yates KB, Ngiow SF, Burke KP, Maleri S, Grande SM, Francisco LM, Ali MA, Imam S, Freeman GJ, Haining WN, Wherry EJ, Sharpe AH. “The PD-1 Pathway Regulates Development and Function of Memory CD8 ⁺ T Cells following Respiratory Viral Infection.” *equal contribution. Cell Reports. 31(13):107827. PMID: 32610128; PMCID: PMC7377452; 2020.

Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. “Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.” Trends in Immunology. 40(6): 511-523. PMID: 31053497; PMCID: PMC6527345; 2019.

Osum KC, Burrack AL, Martinov T, Sahli NL, Mitchell JS, Tucker CG, Pauken KE, Papas K, Appakalai B, Spanier JA, Fife BT. “Interferon-gamma drives programmed death-ligand 1 expression on islet  cells to limit T cell function during autoimmune diabetes.” Sci Rep. 8(1): 8295. PMID: 29844327; PMCID: PMC5974126; 2018.

Sharpe AH and Pauken KE. “The Diverse Functions of the PD1 Inhibitory Pathway.” Nature Reviews Immunology. 18(3): 153-167. PMID: 28990585; 2018.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D’Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George  SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. “T-cell invigoration to tumor burden ratio associated with anti-PD-1 response.” Nature. 545(7652): 60-65. PMID: 28397821; PMCID: PMC5554367; 2017.

Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DS, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ. “Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.” Cell. 167(6): 1540-1554. PMID: 27912061; PMCID: PMC5385895; 2016.

Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen D, Kurachi M, Barnitz RA, Bartman C, Bengsch B, Huang AC, Schenkel JM, Vahedi G, Haining WN, Berger SL, and Wherry EJ. “Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.” Science. 354(6316): 1160-1165. PMID: 27789795; PMCID: PMC5484795; 2016.

Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA, Delgoffe GM, Wherry EJ. “Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion.” Immunity. 45(2): 358-373. PMID: 27496729; PMCID: PMC4988919; 2016.

Manlove LS, Schenkel JM, Manlove KR, Pauken KE, Vezys V, Farrar MA. “Heterologous vaccination and checkpoint blockade synergize to induce anti-leukemia immunity.” Journal of Immunology. 196(11): 4793-4804. PMID: 27183622; PMCID: PMC4875863; 2016.

Martinov T, Spanier JA, Pauken KE, Fife BT. “PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes.” Immunoendocrinology. PMID: 27656680; PMCID: PMC5027981; 2016.

Schenkel JM*, Fraser KA*, Beura LK, Casey KA, Pauken KE, Vezys V, Masopust D. “IL-15 independent maintenance of tissue resident and boosted effector memory CD8 T cells.” *equal contribution. Journal of Immunology. 196(9): 3920-3926. PMID: 27001957; PMCID: PMC5145194; 2016.

Kalekar LA, Schmiel SE, Nandiwada SL, Lam WY, Barsness LO, Zhang N, Stritesky GL, Pauken KE, Linehan JL, Malhotra D, Fife BT, Hogquist KA, Jenkins MK, Mueller DL. “CD4+ T cell anergy prevents autoimmunity and generates regulatory T cell precursors.” Nature Immunology. 17(3): 304-314. PMID: 26829766; PMCID: PMC4755884; 2016.

Gupta PK*, Godec J*, Wolski D, Adland E, Yates K, Pauken KE, Cosgrove C, Ledderose C, Junger WG, Robson SC, Wherry EJ, Alter G, Goulder PJR, Klenerman P, Sharpe AH, Lauer GM, Haining WN. “CD39 expression identifies terminally exhausted CD8+ T cells.” *equal contribution. PLOS Pathogens. 11(10): e1005177. PMID: 26485519; PMCID: PMC4618999; 2015.

Manlove LS, Berquam-Vrieze KE, Pauken KE, Williams RT, Jenkins MK, Farrar MA. “Adaptive immunity to leukemia is inhibited by cross-reactive induced regulatory T cells.” Journal of Immunology. 195(8): 4028-37. PMID: 26378075; PMCID: PMC4592825; 2015.

Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. “Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells.” Journal of Experimental Medicine. 212(7):1125-37. PMID: 26034050; PMCID: PMC4493417; 2015.

Pauken KE*, Nelson CE*, Martinov T*, Spanier JA, Heffernan JR, Sahli NL, Quarnstrom CF, Osum KC, Schenkel JM, Jenkins MK, Blazar BR, Vezys V^#, Fife BT^#. “Identification of autoreactive CD4⁺ and CD8⁺ T cell subsets resistant to PD-1 pathway blockade.” *^,#equal contribution. Journal of Immunology: Cutting Edge. 194(8): 3551-5. PMID: 25769925; PMCID: PMC4390507; 2015.

Twyman-Saint Victor C*, Rech A*, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi R, Schuchter L, Ishwaran H, Mick R, Pryma D, Xu X, Feldman M, Gangadhar T, Hahn S, Wherry EJ^#, Vonderheide RH^#, Minn AJ^#. *,^#equal contribution. “Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.” Nature. 520(7547): 373-7. PMID: 25754329; PMCID: PMC4401634; 2015.

Pauken KE and Wherry EJ. “Snapshot: T cell Exhaustion.” Cell. 163(4): 1038-1038e1. PMID: 26544946; 2015.

Pauken KE and Wherry EJ. “Overcoming exhaustion in infection and cancer.” Review. Trends in Immunology. 36(4): 265-276. PMID: 25797516; PMCID: PMC4393798; 2015.

Pauken KE and Wherry EJ. “TIGIT and CD226: Tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit.” Cancer Cell. 26: 785-787. PMID: 25490444; 2014.

Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust M. “Resident memory CD8 T cells     trigger protective innate and adaptive immune responses.” Science. 346: 98-101. PMID: 25170049; PMCID: PMC4449618; 2014.

Pauken KE, Linehan JL, Spanier JA, Sahli NL, Kalekar L, Binstadt BA, Moon JJ, Mueller DL, Jenkins MK, Fife BT. “Type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice.” Journal of Immunology: Cutting Edge. 191: 4913-4917. PMID: 24123682; PMCID: PMC3987747; 2013.

Pauken KE, Jenkins MK, Azuma M, Fife BT. “PD-1, but not PD-L1, expressed by islet-reactive CD4⁺ T cells suppresses infiltration of the pancreas during Type 1 Diabetes.” Diabetes. 8: 2859-2869. PMID: 23545706; PMCID: PMC3717847; 2013.

Fife BT, Pauken KE. “The role of the PD-1 pathway in autoimmunity and peripheral tolerance.” Immunology Year in Review. Ann. of the NY Aca. of Sciences. Review. Ann N Y Acad Sci. 1217: 45-59. PMID: 21276005; 2011.

Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. “Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.” Nature Immunology. 11: 1185-1192. PMID: 19783989; PMCID: PMC2778301; 2009.

Wheat WH*, Pauken KE*, Morris RV, Titus RG. “Lutzomyia longipalpis salivary peptide maxadilan alters murine dendritic cell expression of CD80/86, CCR7, and cytokine secretion and reprograms dendritic cell-mediated cytokine release from cultures containing allogeneic T cells.” Journal of Immunology. 12: 8286-8298. PMID: 18523295; PMCID: PMC2423730; 2008. *Equal contribution.